Some cancer patients at The University of Texas MD Anderson Cancer Center got an unexpected boost. After receiving the ...

Cancer researchers have chased the idea of a universal cancer vaccine for decades. The promise sounds bold and almost ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Host-Related Determinants of Immunotherapy Response in NSCLC may include obesity, sarcopenia, metabolic comorbidities, sex, ...

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study. The findings ...

Please provide your email address to receive an email when new articles are posted on . More than 50% of adenomas developed within 7.5 months of immune checkpoint inhibitor-mediated diarrhea and ...